Rosty Raykov, a director at Fennec Pharmaceuticals Inc. (NASDAQ:FENC), a company currently valued at $187 million, has sold 10,000 common shares of the company, according to a recent SEC filing.

Fennec Pharmaceuticals Inc. ~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment ...

Q4 2024 Fennec Pharmaceuticals Inc Earnings Call. ... developments that we continue to see is the interest and adoption that we are seeing in the adolescent and young adult segment or AYA.

Stephens initiated coverage of Fennec (FENC) with an Overweight rating and $15 price target The firm is adding to its Biotechnology research coverage with a focus on targeted protein degradation ...

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2024 Earnings Conference Call November 9, 2024 8:30 AM ETCompany Participants. Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive ...